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The drug discovery process classically revolves around a set of biochemical and cellular
assays to drive potency optimization and structural-activity relationship models. Layered
on top of these concepts is the inclusion of molecular features that affect ﬁnal drug use,
things like: bioavailability, toxicity, stability, solubility, formulation, route of administration,
etc. Paradoxically, most drugs entering clinical trials are only tested in a handful of
human genetic backgrounds before they are given to people. Here we review efforts
and opine on the use of large scale in vitro cellular and in vivo models that attempt
to model human disease and include diversity found in the human genetic population.
Because hundreds to thousands of individual assays are needed to scratch the surface of
human genetic diversity, sophisticated high throughput automation technologies or pooling
and deconvolution strategies are required. Characterization of each model needs to be
extensive to enable non-biased informatics based modeling. Such approaches will enable
deep understanding of genetic to pharmacological response and result in new methods
for patient stratiﬁcation in the clinic. Oncology medicines and cancer genetics have been
paving the way for these approaches and we expect to see continued expansion to other
ﬁelds such as immunology and neuroscience.
Keywords: in vitro clinical trials, cell line profiling, cell panels, genetically defined models, iPS derived cell models,
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INTRODUCTION
When a drug discovery project starts, a project team must con-
duct an important thought experiment: if a perfect molecule
that meets all of the team’s criteria was suddenly available, what
patients would be selected and what clinical assays would be used
to demonstrate efﬁcacy. In genetically well-deﬁned diseases this
can be a conceptually straight-forward task. For example inmono-
genic, recessively inherited diseases, like sickle cell anemia or spinal
muscle atrophy, patients are readily identiﬁable by symptoms in
the clinic and conﬁrmed genetically. A homogenous population
of patients provides the best chance of achieving a high signal to
noise readout in the clinical trial. This is because all the patients
should be similar in theirmolecular pathology and patients treated
with a targeted drug should, in an ideal scenario, be obligate
responders.
Cancer, at a fundamental level, is more heterogeneous, but
patient selection strategies have made tremendous strides in
the last decade. An example is the use of Gleevec and other
Abl kinase inhibitors in chronic myelogenous leukemia (CML)
patients that harbor the Philadelphia Chromosome transloca-
tion creating a BCR-Abl gain of function fusion protein. Prior
to the use of Abl inhibitors, approximately 10,000 people in the
US died each year due to CML; that number has dropped to
less than 500 people per year since the introduction of these
drugs to the market. Other examples of therapies “targeted” to
selected cancer types are abundant and include B-RAF, C-KIT,
p53-MDM2, c-MET, JAK1, and EGFR. In many cases these ther-
apies lead to a remission, not a cure, and this is likely a reﬂection
of the genetic heterogeneity of the original tumor and a result
of the subsequent selective pressure under drug treatment that
enable resistant cells to continue to grow. Ultimately, this will
lead to drug resistance. New next gen sequencing (NGS) tech-
nologies are tremendously impacting the ﬁeld’s understanding
of the spectrum of mutations and underlying heterogeneity in
a tumor.
Other “common” diseases, like Alzheimer’s disease, Type II
Diabetes, and Schizophrenia are thought to be at least partially
driven by common genetic variants. The genetics are compli-
cated but the prevailing theory is that small changes in gene
regulation, likely at the level of mRNA, slightly predispose an
individual for a disease. As subtle genetic variations accumulate
in an individual, that person’s risk of developing the disease also
increases. Due to this, genetic stratiﬁcation in common disease
populations is extremely difﬁcult. Nonetheless, common variant
research has identiﬁed examples where genetic testing of patients
can be used to select patients for clinical trials. These include
people who are homozygous for a common variant in APOE,
ApoE4, whom are 10 times more likely to develop Alzheimer’s
Disease relative to persons not harboring the ApoE4 variant.
An excellent review by Plenge et al. (2013) draws connections
between common variants and disease understanding; it out-
lines strategies for using genome wide association studies and
other human genetic data to select drug targets and stratify
patients.
Cancer therapeutics have already beneﬁtted from the use of
genetically deﬁned human cell panels. This approach should
be applicable to monogenic neurological disorders and eventu-
ally to other indications where predictive cellular models can be
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generated. The goal of “in vitro clinical trials” will be to change
the arc of drug development, from a paradigm where many thera-
pies are dropped between optimization and candidate selection
(Figure 1). Human cellular models will help bridge this gap
(as illustrated in Figure 1, dashed line), speeding the develop-
ment of new drugs and our understanding of human disease.
In this Technology Report, we aim to highlight past examples
of cell panel screens and point to future applications of the
approach that will extend past cancer to rapidly evolving areas like
neurobiology.
GENETIC STRATIFICATION WITH CANCER CELL LINES –
HISTORICAL PERSPECTIVE
In the late 1980’s the national cancer institute (NCI) began proﬁl-
ing a set of approximately 60 human cancer cell lines in what
became known as the NCI-60 panel (Shoemaker, 2006). The
proﬁling platform was the ﬁrst to enable researchers with drug
candidates to ﬁnd out whether their molecule of interest displayed
any selectivity towards certain cancers and to focus a molecule
in indications based on pre-clinical data. What was remarkable
about the effort was the realization that cancer cell lines could
capture some of the diversity of patient cancers and that with
brute force effort, one could emulate a small scale clinical trial
resulting in some predictive value. The NCI-60 was also pioneer-
ing from a technical perspective, establishing rigorousmethods for
genetically distinguishing cell lines from each other and enabling
methods for large scale data analysis across many cell lines and
compound treatments so that overlapping bioactivity between
small molecules could be easily observed. Some of the major ﬁnd-
ings that have emerged from the NCI-60 effort include the link
between TGFα-PE38 and EGFR expression, halichondrin B being
identiﬁed as a microtubule inhibitor, and bortezomib/VelcadeTM
as a proteasome inhibitor. Additionally, the recognition that cells
could pump out a small molecule via the multidrug resistance
pump (e.g., MDR and PgP) and that this could be modeled
across cell lines could only be appreciated in the context of a
panel of cell lines; the NCI-60 effort was truly pioneering in this
approach.
The evolutionof approaches tomeasure genomic chromosomal
aberrations led Garraway and Sellers to look for genetic ampliﬁca-
tions across the NCI-60 panel of cell lines as a potential means to
identify new oncogenic drivers (Garraway et al., 2005). This work
led to the discovery of microphthalmia-associated transcription
factor (MITF) as a lineage speciﬁc oncogenic transcription fac-
tor in melanoma. Using single nucleotide polymorphism (SNP)
arrays, the NCI-60 cell lines, spanning nine different cancer lin-
eages, were assayed for chromosomal alterations. Hierarchical
clustering was used to organize the cell lines by copy number
alteration and the observation was made that the cell lines largely
clustered by cancer type leading the authors to postulate that
the chromosomal alterations driving these clusters might contain
lineage-speciﬁc cancer genes. One of the most striking clusters
was chromosome 3 (3p13–3p14) in the melanoma lineage. In
their subsequent studies the authors used gain-of-function and
loss-of-function approaches to demonstrate that MITF is capable
of cooperating with mutant BRAF to transform normal cells and
that MITF knockdown causes loss of viability in MITF copy-gain
melanoma cells. This study served as another example of the early
use of cell panels and their utility in leading to signiﬁcant biolog-
ical discovery that would not have been possible with individual
disease models.
The approach taken by Garraway and Sellers was further
extended in a report by Solit et al. (2006) where the genetic com-
position of the NCI-60 cell lines was compared against compound
activity proﬁles, allowing the authors to link MEK inhibition to
BRAF mutant melanoma. Subsequent studies have led to new
applications such as that of Neve et al. (2006). Using a panel of
51 breast cancer cell lines and Trastuzumab, they identiﬁed an
important relationship between HER2 ampliﬁcation status and
response to Trastuzumab treatment (Neve et al., 2006).
FIGURE 1 |The goal of “in vitro clinical trials” is to use genetically characterized cell panels in an effort to reduce the number of potential therapies
dropping out of clinical development before entering clinical trials and to better inform patient stratification.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery May 2014 | Volume 5 | Article 121 | 2
Ross andWilson In vitro clinical trials
Pushing the cancer cell panel approach further, McDermott
et al. (2007) established a panel of 500 cancer cell lines and tested
14 kinase inhibitors across this panel of lines. Their data con-
ﬁrmed the established relationships between EGFR, HER2, MET,
and BRAF inhibitors and cell lines with the respective mutant
gene. As had been observed previously at the NCI, the cell panel
approach allowed for compounds with similar bioactivity proﬁles
to be grouped together, revealing previously unappreciated biolog-
ical activity and/or compoundpolypharmacology. In a subsequent
manuscript McDermott et al. (2008) expanded their cell panel to
602 cell lines anddetailed the relationships betweenALK inhibitors
and ALK mutant cancers. More recently several teams have estab-
lished large cell line panels of > 500 cancer cell lines and have
published proﬁling results of a sub-set of the compounds screened.
These efforts include those of MGH/Sanger group (Garnett et al.,
2012) and theBroad/NovartisCancerCell LineEncyclopedia effort
(Barretina et al., 2012). There are several good reviews on the
development of these large scale cancer cell panels (Shoemaker,
2006; Sharma et al., 2010; Caponigro and Sellers, 2011) and their
application to patient selection and pharmacological compound
analysis.
TECHNICAL CONSIDERATIONS FOR THE SUCCESSFUL
APPLICATION OF CELL PANELS AND OPPORTUNITIES FOR
IMPROVEMENT
Many of the same challenges that were faced by the NCI-60 team
in the 1980’s still exist today. First among these is the quality
control (QC) of cell line identity. As has been the case since
the inception of the cancer cell line screening panel, knowing
the absolute identity of each cell line screened is critical for
all subsequent analyses. Early on, HeLa cell contamination was
mitigated by cytogenetic testing of cell lines via chromosome
banding (Shoemaker, 2006). This process was also able to tease
out cell lines derived from a common origin, adding an impor-
tant layer of information for future data analyses. Since this
time, technology in the ﬁeld has evolved, starting with restric-
tion length polymorphism analysis, on to DNA ﬁngerprinting,
then spectral karyotyping, and most recently, short tandem repeat
(STR) or SNP testing. Other practices for QC, important in the
past and still relevant today, are mycoplasma testing of all cell
lines at each iteration of a panel screen and limiting the exper-
iment to a common media type for tissue culture. In recent
years, high-precision automation and the use of 1536-well for-
mat cellular assays have vastly increased the throughput at which
cancer cell line panels can be screened. While this is power-
ful in light of the volume of data generated, which can lead
to more interesting correlations of compound-cell activity, the
requirement for appropriate QC measures will be even more
important.
Much like the technology for cell line QC, assay readouts have
also advanced over the last 30 years. NCI’s pioneering work led
to the development of a high throughput screening assay using
sulphorhodamine B as a read out (Shoemaker, 2006). This assay
proved robust and conveniently included a ﬁxation step before
reading, which was highly desirable before the advent of modern
automation equipment. Other early examples of large scale screen-
ing used 96-well plates and a cell-ﬁxation assay with a ﬂuorescent
nucleic acid stain (McDermott et al., 2007). These protocols were
modernized as part of the Cancer Cell Line Encyclopedia (CCLE)
effort, when industrial-scale screening systems were brought to
bear on the cell proﬁling challenge. In the published CCLE screen
Novartis adapted the assay to 1536-well format and used Cell Titer
Glo (Promega) as a one-step luminescent assay for cell viability
(Barretina et al., 2012). However, even in this modern interpre-
tation of the NCI-60 assay some methods remain the same, such
as ﬁxed seeding densities and standard media for all cell lines
tested.
While proper QC is essential for yielding good data, selection
of the ideal metrics for comparing compound response pro-
ﬁles across cell line panels is central to turning good data into
impactful data. Today’s myriad methods for genetically charac-
terizing cell lines offer many possibilities for dissecting the details
of compound activity and cell-line responsiveness. Early efforts
in this area include COMPARE for NCI-60 compound proﬁles
(Shoemaker, 2006) and CellMiner (Shankavaram et al., 2009) for
compound-genetic feature comparisons. Beyond the genetic fea-
ture correlations, there are a number of other parameters that
can add to the complexity, such as dose-response curve IC50 (or
crossing point), curve inﬂection point, activity area (or area under
the curve), and maximal activity, frequently being utilized (Bar-
retina et al., 2012). Most recently, Fallahi-Sichani et al. (2013) have
demonstrated that incorporation of the concentration-response
curve slope, area under the curve, and maximal effect can also
yield insights into the mechanism of cell-death and also identify
cell-to-cell variability in drug response.
Further insight can be gained by collecting more complex
genetic information. Recently Jaffe et al. (2013) conducted global
chromatin mass spectrometry proﬁling of 115 cancer cell lines.
A common internal standard allowed for comparison of relative
methylation and acetylation levels of all lysine residues on his-
tone H3 between cell lines. This led to the observation that a
set of cell lines had increased histone 3 lysine 36 dimethylation
and that these lines contained either a t(4;14) translocation or a
previously unknown coding mutation in the histone 3 lysine 36
methyltransferase NSD2, which was later shown to be an activat-
ing mutation. The t(4;14) translocation is known to drive high
expression of NSD2, providing further support for the overlap-
ping histone methylation proﬁle of these cell lines. Increasing the
depth of characterization of cancer cell lines will likely lead to
further novel observations such as those described here.
MOVING BEYOND CANCER CELL LINES
Even at the earliest stages of the NCI-60 cell panel project,
the importance of transitioning from cancer cell lines to ani-
mal models of cancer was recognized. Limitations to can-
cer cell lines include inherent biases towards speciﬁc cell
signaling and growth pathways that favor growth in cell
culture. For example PI3Kalpha, RAS, and BRaf muta-
tions are well represented in cancer cell lines. However,
some pathway mutations are not well represented in cell
lines, for example the hedgehog pathway, via smoothened
(SMO) and GLI1/2/3 mutations do not appear in any known
cell line and no cell line is responsive to SMO antago-
nists (ref: http://www.ncbi.nlm.nih.gov/pubmed/20881279 and
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unpublished results). Another example are IDH1 and IDH2 gain
of function mutations that are commonly found in Glialblastoma
and AML in clinical settings, yet very few, one or two, cell lines
harbor these activating mutations. Therefore, the new generation
of IDH1 inhibitors cannot be tested in standard cell proliferation
models.
Two new approaches have capitalized on this idea, instead per-
forming panel based screening directly in mice. These are referred
to as “mouse avatars” and mouse “co-clinical trials” and both were
recently reviewed by Malaney et al. (2014). The “mouse avatar”
approach (also known as “xeno-patient trials”) utilizes patient
derived tumor xenograft models (PDTX), which rely on implan-
tation of patient tumor samples into immunocompromised mice
for study with pharmacological tool compounds. Tumor sam-
ples are genetically characterized both when removed from the
patient as well as at intervals after transplantation into mice. While
PDTX models have been generated for most major human cancers
many challenges still remain for this platform to bewidely adopted
(cost and engraftment difﬁculty); however, we anticipate that the
approach will continue to grow in prominence.
The second concept of mouse “co-clinical trials” involves using
genetically engineered mouse models (GEMMs) in parallel with
on-going human clinical trials as a way of anticipating response
in the human arm of the trial (Nardella et al., 2011). Several
co-clinical trials with GEMMs have been initiated recently with
mixed results. In a successful example, Chen et al. (2012) have
tested the use of the MEK inhibitor selumetinib in combina-
tion with docetaxel in a KRAS-mutant lung cancer trial. This
effort led to the observation that the combination therapy out-
performed monotherapy in cases where KRAS mutation alone
or KRAS and p53 mutation were both present; however, mice
with KRAS and LKB1 mutation were resistant to the combi-
nation therapy. This data suggests that patients in the clinical
trial should be screened for LKB1 mutations in parallel as
they may become resistant to therapy. This result, and others
like it, could have a signiﬁcant impact on the human arm of
the co-clincial trial and could inform patient stratiﬁcation for
future human trials as well. We anticipate that co-clinical tri-
als will be focused in nature compared to more exploratory
cell line panel screens, but could impact the shape of human
clinical trials and inﬂuence their outcomes while the trial is in
progress.
USING CELLULAR MODELS IN NON-ONCOLOGY FIELDS
Beyond oncology indications, immunological proﬁling of patient
derived blood cells represents a fruitful and relatively straightfor-
ward method to proﬁle drug candidates across human genomic
variation. From blood draws, peripheral blood mononuclear cells
(PBMCs) can be isolated and are commonly used in experiments;
large numbers of patient samples can be proﬁled with this ready
source of cells. A key issue to using PBMCs is that they are a
mixed cell population representing many of the various immuno-
logical lineages, including B and T cells, macrophages, etc. Until
recently this represented a signiﬁcant hurdle because only a few
bulk attributes could be used to monitor response to compounds
thus the cellular and mechanistic resolution was not nearly high
enough. Advances in single cell analytical techniques have changed
the landscape and now enable researchers to examine individual
cellular responses.
Bodenmiller et al. (2012) recently described a clever proof of
concept experiment using a new instrument called a CyTof. The
CyTof is essentially a cell sorter that measures mass tags rather
than ﬂuorescent tags typical of a FACS instrument. The higher
resolution of the mass spectrometer enables a 10–50x improve-
ment in the number of tags that can be read per cell, and this
enables identiﬁcation of each cell type in the sorting along with
multiple signaling pathway readouts on a per cell basis. In their
study, PBMCs from eight patients were collected and separated
into 14 cell types and further sub-division is possible. They simul-
taneously measured well characterized signaling cascade markers
in each cell, like phospho-ERK and phoso-STAT5 in the pres-
ence and absence of different immuno stimulatory treatments
such as LPS and Interferon-gamma. The data clearly show that
cell type speciﬁcity is achieved, for example only cell types that
express TLR4 respond to the LPS stimulation. What makes the
study exceptional is that they then look at the responses across
all these condition in the context of about 30 drugs or drug-
like tool molecules. The authors generally see similarities between
the different patient samples, but do note occasional differences,
suggestive of environmental or genetic differences.
While the Bodenmiller study was not powered or designed to
explore the genetic or environmental factors that may give rise
to these subtleties, it is not a far stretch to imagine hundreds of
patients or even longitudinal studies examining ex vivo response
of PBMCs to various stimuli and drug candidates. Differential
response between subjects could be explored in more depth with
the goal of correlating and attributing genetic or environment fac-
tors (for example allergies that immuno activate cells and immuno
inhibitory anti-histamines) to mechanistic changes in cell speciﬁc
signaling pathways. Additionally, improvements are being made in
single cell mRNA detection technologies and these are an attrac-
tive alternative to the CyTof technology due to enhanced ﬂexibility
of nucleic acid detection technologies (Ståhlberg and Bengtsson,
2010; Shalek et al., 2013). From these types of studies, predictive
and stratifying biomarkers could be built and deployed to build
clinical trials with better signal to noise ratios.
iPS DERIVED CELLS
Induced Pluripotent Stem Cell technology has created a mas-
sive paradigm shift in disease modeling. Originally described by
Takahashi et al. (2007), the introduction of a handful of “repro-
graming” transcription factors can revert easy to acquire ﬁbrob-
lasts and blood cells to a pluripotent state. These pluripotent cells
can then be differentiated into many different cell types and cell
structures. Neural progenitors and various types of neurons turn
out to be one of the more straight-forward cell types to make
and these neuronal models were simply not available to the gen-
eral research community previously; most researchers use rodent
derived primary neurons as a cellular model. Heart, liver, eye, and
many other cell types can also be generated. These cells can be
grown is a more traditional 2D cell model and also in 3D organ
like precursors, including recent reports of cerebral organoids, also
known as mini-brains (Lancaster et al., 2013). These multicellular
structures are often limited in growth simply by the lack of blood
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innervation and lack of oxygenation. This is a highly active ﬁeld
of research and we should expect many innovations in the future.
Because iPS use relatively standard cell culture techniques there
are already many efforts in academia and commercial ventures to
scale up collections. A particularly good and recent review written
by McKernan and Watt (2013) details many ongoing large scale
collection efforts. Summing all the efforts listed in that review
there are currently ∼150 cell lines available from public institu-
tions, but there could be more than 20,000 cell lines from 10,000
individuals available in the next 3–5 years. With good data ascer-
tainment for both clinical characterization and genetic proﬁling,
these collections could be enormously valuable.
Most iPS and neuronal disease modeling to date has focused
on highly penetrant monogenic diseases. In these experiments
researchers collect cells fromdiseased and normal control patients,
reprogram them to iPS states and differentiate them into vari-
ous neuronal subtypes. Typically characterization of the neurons
leads to discovery of a difference in phenotype that reﬂect the
disease state and that, in turn, enables a platform for further
characterization and functional screening. Examples here include
Pheland–McDermid syndrome (Shcheglovitov et al., 2013), Tim-
othy Syndrome (Pas¸ca et al., 2011; Yazawa et al., 2011; Krey
et al., 2012), ALS (Di Giorgio et al., 2008; Dimos et al., 2008),
and there are many others. Expanding these collections across
large numbers of monogenic diseases offers an opportunity to
standardize the QC and neuronal differentiation procedures. Uni-
versal assay formats, such as mRNA readouts for cell types or
neuronal activity, or activity measures using a system like the
MANTRA (Hempel et al., 2011), can be used when pharmaco-
logically proﬁling. For example, a collection of 250 iPS derived
cortical neurons from 25 monogenic diseases (10 lines per disease)
could be proﬁled across hundreds of drugs or drugs candi-
dates using mRNA activity markers. Questions could be asked
like what drugs increase the levels of speciﬁc synaptic activ-
ity markers such as Arc or c-Fos. When contextualized across
large numbers of cell lines and compounds, this should reduce
potential biases for interpretation and lead to robust results.
Although these numbers of iPS cells are considered extremely
large for most labs, groups like the New York Stem Cell Foun-
dation (http://www.nyscf.org/) have successfully automated many
of the processes associated with culturing stem cells and offer
hope on the path to achieving assays scale with iPS derived
cells.
One criticism of the this approach is that it is conceptually
limited to severe monogenetic disease where penetrance is very
high in patients and the expectation is that distinctive iPS derived
neuronal phenotypes are related to the disease. Polygenic diseases
with high heritability, like schizophrenia, present a much greater
challenge. The genetic variants associated with these “common”
diseases are thought to exert only a small change to disease risk,
and presumably cellular phenotype. Deﬁning what the disease
associated variants do at a functional level is a key driver for cur-
rent research (see commentary by Edwards et al., 2013). Many,
if not most, are thought to exert subtle mRNA expression level
changes, often confusingly called eQTLs. Because these affects are
small andbecause speciﬁc gene regulation canbebiasedby genome
background, hundreds, maybe thousands or tens of thousands of
neurons will need to be molecularly and then pharmacologically
proﬁled. Luckily these large scale iPS collections are now com-
ing together. Additionally because common variants are present
at rates > 5% throughout the population there is no need to
collect harder to get disease patient samples and instead healthy
volunteers can be used.
CONCLUSION
Using large numbers of human cellular models is a proven method
to identify patients and the fundamental genetics responsible for
disease and drug response. These models have been used for
decades to characterize mid to late stage pre-clinical drugs in
oncology (e.g., the NCI-60). In the last 5–7 years it has been shown
by the CCLE and similar efforts that expanding the numbers of
cellular models by 10-fold dramatically improves the resolution
of the genetic models and enables discovery of the fundamen-
tal biology of tumor growth. Similar strategies can be used for
immunological proﬁling of blood cells or neurological proﬁling
of iPS derived neurons. Scaling up these processes will involve
signiﬁcant investments in infrastructure, methods, and QC to
achieve reliable models, especially in the nascent iPS derived
neuron ﬁeld. Improvements in sequencing and genetics tech-
nologies are far exceeding the ability to build animal models
and we believe that these human models will be more predic-
tive by reﬂecting the patient diversity presented by people in the
clinic.
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